ADAG
Adagene Inc.
$3.57
-0.28%
$235.8M
No data for this timeframe.
Vol
Market Cap$235.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders9 funds
Inst. Value$3.2M
Inst. Activity1 buys / 1 sells
SEC Reports4
Press Releases4
Recent Activity
Apr 17, 2026
SEC
Adagene presented new clinical data at AACR 2026 showing strong efficacy for muzastotug in triple combination therapies:
6-K — Impact 8/10
Apr 2, 2026
SEC
Adagene Inc. has entered into an underwriting agreement to raise approximately $70.0 million through the public offering
6-K — Impact 7/10
Apr 2, 2026
SEC
Adagene Inc. is conducting a preliminary prospectus supplement for a public offering of American Depositary Shares (ADSs
424B5 — Impact 5/10
Inst.
FIL Ltd — NEAR_EXIT
749,448 shares ($1.2M)
Inst.
ROYAL BANK OF CANADA — ADD
16,850 shares ($26.0K)
May 12, 2026
other
Adagene to Participate in Two Upcoming Investor Conferences
<p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adage
Apr 2, 2026
Press
Adagene priced a public offering of 18.7M ADSs at $3.75 per share, raising approximately $70.0 million in gross proceeds
Impact 5/10
Apr 2, 2026
Press
Adagene announced a clinical collaboration with Incyte to evaluate its masked anti-CTLA-4 therapy muzastotug in combinat
Impact 7/10
Price Targets
$9.40
+163.3% upside
Strong Buy
Current $3.57
Low $7.00
Median $8.00
High $14.00
5 analysts
$7.00
$14.00
Analyst Ratings
4Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 6, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.08 ▲ +68.0% | $-0.08 — $-0.08 | 1 | |
| Next Q | $-0.19 | $-0.19 — $-0.19 | 1 | |
| Current FY | $-0.51 ▲ +29.2% | $-0.51 — $-0.51 | -113% YoY | 1 |
| Next FY | $-0.52 ▲ +32.5% | $-0.52 — $-0.52 | -2% YoY | 1 |
Latest Reports
BULLISH
6-K
8/10
Adagene presented new clinical data at AACR 2026 showing strong efficacy for muzastotug in triple combination therapies:
Apr 17, 2026
BEARISH
6-K
7/10
Adagene Inc. has entered into an underwriting agreement to raise approximately $70.0 million through the public offering
Apr 2, 2026
NEUTRAL
Press
5/10
Adagene priced a public offering of 18.7M ADSs at $3.75 per share, raising approximately $70.0 million in gross proceeds
Apr 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| AMERIPRISE FINANCIAL INC | $2.4M | — |
| MORGAN STANLEY | $259.3K | — |
| Invesco Ltd. | $184.7K | — |
| RENAISSANCE TECHNOLOGIES LLC | $135.4K | — |
| Alyeska Investment Group, L.P. | $81.2K | — |
9 institutional holders with $3.2M total value (809,013 shares) as of 2026-Q1. Top holders: AMERIPRISE, MORGAN, Invesco.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | AMERIPRISE FINANCIAL INC | 607,903 | $2.4M | 75.1% | — |
| 2 | MORGAN STANLEY | 66,148 | $259.3K | 8.2% | — |
| 3 | Invesco Ltd. | 47,124 | $184.7K | 5.8% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 34,533 | $135.4K | 4.3% | — |
| 5 | Alyeska Investment Group, L.P. | 20,710 | $81.2K | 2.6% | — |
| 6 | ROYAL BANK OF CANADA | 16,850 | $66.0K | 2.1% | ADD +30.1% |
| 7 | NOMURA HOLDINGS INC | 14,710 | $57.7K | 1.8% | — |
| 8 | BlackRock, Inc. | 635 | $2.5K | 0.1% | — |
| 9 | BARCLAYS PLC | 400 | $1.6K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FIL Ltd | NEAR_EXIT | 3,274,798 | 749,448 | -77.1% | $1.2M | 2025-Q1 |
| ROYAL BANK OF CANADA | ADD | 12,950 | 16,850 | +30.1% | $26.0K | 2025-Q1 |
| ROYAL BANK OF CANADA | ADD | 8,300 | 12,950 | +56.0% | $26.0K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 6.8/10.
BULLISH
6-K
8/10
Adagene presented new clinical data at AACR 2026 showing strong efficacy for muzastotug in triple co
Apr 17, 2026
BEARISH
6-K
7/10
Adagene Inc. has entered into an underwriting agreement to raise approximately $70.0 million through
Apr 2, 2026
NEUTRAL
424B5
5/10
Adagene Inc. is conducting a preliminary prospectus supplement for a public offering of American Dep
Apr 2, 2026
BULLISH
20-F, 6-K
7/10
Adagene's 20-F filing, combined with recent 6-Ks, confirms strong clinical progress for its lead can
Apr 1, 2026
NEUTRAL
5/10
Adagene priced a public offering of 18.7M ADSs at $3.75 per share, raising approximately $70.0 milli
Apr 2, 2026
BULLISH
7/10
Adagene announced a clinical collaboration with Incyte to evaluate its masked anti-CTLA-4 therapy mu
Apr 2, 2026
BULLISH
8/10
Adagene announced updated Phase 1b/2 data for muzastotug in advanced MSS CRC, showing a 31% confirme
Apr 2, 2026
NEUTRAL
5/10
Adagene Inc. announced that its lead candidate, muzastotug (ADG126), will be featured in two poster
Mar 17, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 4 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.40 mean target
+163.3% upside
Strong Buy (3.00)
$7.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $3.57 |
| Target Low | $7.00 |
| Target Mean | $9.40 |
| Target Median | $8.00 |
| Target High | $14.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.08 | $-0.08 | $-0.08 | — | +68.0% | — | $0.0B | — | 1 |
| Next Q 2026-06-30 |
$-0.19 | $-0.19 | $-0.19 | — | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.51 | $-0.51 | $-0.51 | -112.5% | +29.2% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-0.52 | $-0.52 | $-0.52 | -2.0% | +32.5% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.080 | |
| 7d ago | $0.000 | -0.080 |
| 30d ago | $-0.250 | +0.170 |
| 60d ago | $-0.250 | +0.170 |
| 90d ago | $-0.250 | +0.170 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Jan 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
other
Adagene to Participate in Two Upcoming Investor Conferences
<p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company tran
Apr 17, 2026
other
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
<p align="center"><em>Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to t
Apr 2, 2026
activist
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
<p align="justify">SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a compa
Apr 2, 2026
fda
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
<p align="center"><em>Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients</em> <em>with and without liver metas
Apr 2, 2026
fda
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
<p align="center"><strong><em>Dose-Dependent Efficacy Results</em></strong><em>: As of the latest data cut, muzastotug</em> <em>achieved a 31% (8/26)
Apr 1, 2026
earnings
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
<p align="center"><em>In 2025, muzastotug</em> <em>showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dos
Mar 23, 2026
earnings_calendar
ADAG Q4 2025 Earnings After Market Close — 2026-03-23
Mar 17, 2026
fda
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
<p align="justify">SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company